FDA Committee Endorses New Blood Test for Colon and Rectal Cancer Screening

FDA Committee Endorses New Blood Test for Colon and Rectal Cancer Screening | Enterprise Wired

Share Post:

LinkedIn
Twitter
Facebook
Reddit
Pinterest

Source – CNN

A committee of experts advising the Food and Drug Administration (FDA) overwhelmingly voted in favor of a new blood test designed to screen individuals for colon and rectal cancers. Despite acknowledging certain limitations, the committee concluded that the test, known as Shield and manufactured by Guardant Health, was both safe and effective, with its benefits outweighing potential risks.

Addressing Low Screening Rates

The committee’s endorsement of the blood test comes in response to alarmingly low screening rates for colon and rectal cancers in the United States. With approximately 150,000 new diagnoses and an estimated 53,000 deaths attributed to these cancers annually, effective screening methods are critical for early detection and treatment. Currently, most screenings involve invasive procedures like colonoscopies or fecal tests, which may deter individuals from undergoing regular screening.

Convenience vs. Accuracy

Unlike traditional screening methods, the Shield blood test offers convenience for individuals with an average risk of colon and rectal cancer. With no need for extensive preparation, fasting, or anesthesia, the blood test presents a more accessible option for screening. However, experts caution that its accuracy falls short compared to colonoscopies, particularly in detecting precancerous growths that could be removed to prevent cancer development.

Balancing Risks and Benefits

While the blood test may miss certain precancerous growths, its potential to increase screening rates among individuals who would otherwise avoid traditional methods is seen as a significant benefit. The FDA committee weighed the risk of the blood test overlooking dangerous polyps against the likelihood of expanding screening accessibility and concluded that any form of screening is preferable to none at all.

Looking Ahead

If approved by the FDA, the Guardant Health blood test could revolutionize colon and rectal cancer screening by offering a convenient alternative for individuals at average risk. While acknowledging its limitations, proponents argue that increasing screening rates could ultimately save lives by facilitating earlier detection and treatment. As the FDA evaluates the test for approval, the hope is that it will provide a valuable tool in the ongoing battle against colorectal cancer.

Curious to learn more? Explore our articles on Enterprise Wired

RELATED ARTICLES

The Allure and Controversy of Zillow’s Zestimate: A Digital Real Estate Revolution

The Allure and Controversy of Zillow’s Zestimate: A Digital Real Estate Revolution

A Game-Changer in Real Estate Valuation Zillow’s Zestimate, introduced in 2006, transformed how Americans viewed real estate. Promising a “free,…
Starbucks Baristas Launch Strikes in Three Major Cities Amid Labor Disputes

Starbucks Baristas Launch Strikes in Three Major Cities Amid Labor Disputes

Workers Protest Unresolved Labor Issues Starbucks baristas in Los Angeles, Chicago, and Seattle have begun striking, marking a significant escalation…
Big Lots Begins 'Going Out of Business' Sales Amid Financial Struggles

Big Lots Begins 'Going Out of Business' Sales Amid Financial Struggles

Retailer Announces Sales at All Remaining Locations National retailer Big Lots, based in Columbus, Ohio, has announced the commencement of…
US Federal Reserve Cuts Interest Rates but Signals Slower Easing Ahead

US Federal Reserve Cuts Interest Rates but Signals Slower Easing Ahead

Fed Maintains Caution Amid Economic Stability The United States Federal Reserve announced a Fed rate cut while signaling a more…